CA2616069C - Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin - Google Patents
Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin Download PDFInfo
- Publication number
- CA2616069C CA2616069C CA2616069A CA2616069A CA2616069C CA 2616069 C CA2616069 C CA 2616069C CA 2616069 A CA2616069 A CA 2616069A CA 2616069 A CA2616069 A CA 2616069A CA 2616069 C CA2616069 C CA 2616069C
- Authority
- CA
- Canada
- Prior art keywords
- immunoglobulin
- cell
- transgenic
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 189
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 189
- 241001465754 Metazoa Species 0.000 title claims abstract description 173
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 132
- 230000024704 B cell apoptotic process Effects 0.000 title claims description 5
- 230000001629 suppression Effects 0.000 title description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 136
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims abstract description 96
- 239000000158 apoptosis inhibitor Substances 0.000 claims abstract description 96
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 93
- 108700019146 Transgenes Proteins 0.000 claims abstract description 92
- 230000014509 gene expression Effects 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 claims abstract description 30
- 230000004083 survival effect Effects 0.000 claims abstract description 29
- 230000002708 enhancing effect Effects 0.000 claims abstract description 20
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims abstract description 15
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 32
- 241000287828 Gallus gallus Species 0.000 claims description 29
- 235000013330 chicken meat Nutrition 0.000 claims description 27
- 238000003776 cleavage reaction Methods 0.000 claims description 27
- 230000007017 scission Effects 0.000 claims description 27
- 238000012250 transgenic expression Methods 0.000 claims description 27
- 241000283690 Bos taurus Species 0.000 claims description 24
- 241001494479 Pecora Species 0.000 claims description 19
- 239000004365 Protease Substances 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 19
- 102000037865 fusion proteins Human genes 0.000 claims description 19
- 241000271566 Aves Species 0.000 claims description 17
- 102000035195 Peptidases Human genes 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 239000003623 enhancer Substances 0.000 claims description 17
- 241000283707 Capra Species 0.000 claims description 14
- 210000004102 animal cell Anatomy 0.000 claims description 14
- 241000283074 Equus asinus Species 0.000 claims description 13
- 241000283086 Equidae Species 0.000 claims description 12
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 11
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 11
- 241000283984 Rodentia Species 0.000 claims description 11
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 10
- 241001648840 Thosea asigna virus Species 0.000 claims description 10
- 241000283073 Equus caballus Species 0.000 claims description 9
- 241000282887 Suidae Species 0.000 claims description 9
- 241000214054 Equine rhinitis A virus Species 0.000 claims description 8
- 241000282898 Sus scrofa Species 0.000 claims description 8
- 206010039083 rhinitis Diseases 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 5
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 108090001126 Furin Proteins 0.000 claims description 4
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 4
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 claims description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 4
- 101710132152 Immunoglobulin J chain Proteins 0.000 claims description 4
- 102100020744 Immunoglobulin iota chain Human genes 0.000 claims description 4
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 101100381517 Mus musculus Bcl2 gene Proteins 0.000 claims description 4
- 101100381649 Mus musculus Bik gene Proteins 0.000 claims description 4
- 101100381845 Mus musculus Blk gene Proteins 0.000 claims description 4
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 4
- 102000035100 Threonine proteases Human genes 0.000 claims description 4
- 108091005501 Threonine proteases Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 102000004961 Furin Human genes 0.000 claims 2
- 230000001965 increasing effect Effects 0.000 abstract description 9
- 230000016784 immunoglobulin production Effects 0.000 abstract description 6
- 230000008878 coupling Effects 0.000 abstract description 3
- 238000010168 coupling process Methods 0.000 abstract description 3
- 238000005859 coupling reaction Methods 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 127
- 108020004414 DNA Proteins 0.000 description 37
- 239000000427 antigen Substances 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 32
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 30
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 23
- 230000008707 rearrangement Effects 0.000 description 22
- 229940072221 immunoglobulins Drugs 0.000 description 21
- 239000013598 vector Substances 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 101150117115 V gene Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 229930182566 Gentamicin Natural products 0.000 description 11
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 11
- 241000282412 Homo Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 241000272517 Anseriformes Species 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 235000019419 proteases Nutrition 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- -1 caspase-9S Proteins 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000000287 oocyte Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 6
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 101150008942 J gene Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 241000286209 Phasianidae Species 0.000 description 5
- 101100231696 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FRT2 gene Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 4
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 4
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 101000896157 Homo sapiens Baculoviral IAP repeat-containing protein 2 Proteins 0.000 description 4
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 101150097493 D gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000003526 lymphopoietic effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 101150098466 rpsL gene Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- SPBWHPXCWJLQRU-FITJORAGSA-N 4-amino-8-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C12=NC=NC(N)=C2C(=O)C(C(=O)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SPBWHPXCWJLQRU-FITJORAGSA-N 0.000 description 2
- 241000317943 Acute bee paralysis virus Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 2
- 102100027955 BAG family molecular chaperone regulator 4 Human genes 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 2
- 101710178008 Baculoviral IAP repeat-containing protein 6 Proteins 0.000 description 2
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 2
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 2
- 101710178104 Baculoviral IAP repeat-containing protein 8 Proteins 0.000 description 2
- 108700032588 Baculovirus p35 Proteins 0.000 description 2
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 2
- 241000710127 Cricket paralysis virus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000907524 Drosophila C virus Species 0.000 description 2
- 101000928788 Drosophila melanogaster Death-associated inhibitor of apoptosis 2 Proteins 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101000697866 Homo sapiens BAG family molecular chaperone regulator 4 Proteins 0.000 description 2
- 101100272581 Homo sapiens BIRC7 gene Proteins 0.000 description 2
- 101000896224 Homo sapiens Baculoviral IAP repeat-containing protein 3 Proteins 0.000 description 2
- 101000896234 Homo sapiens Baculoviral IAP repeat-containing protein 5 Proteins 0.000 description 2
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 2
- 101000629913 Homo sapiens Translocon-associated protein subunit beta Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150055501 K1 gene Proteins 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101000896227 Mus musculus Baculoviral IAP repeat-containing protein 5 Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 2
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100026229 Translocon-associated protein subunit beta Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 108091010988 fibronectin binding proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- IEYFRQLMJACEQY-UHFFFAOYSA-N 16-iodo-3-methylhexadecanoic acid Chemical compound OC(=O)CC(C)CCCCCCCCCCCCCI IEYFRQLMJACEQY-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000585705 Alicia <angiosperm> Species 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101710166261 B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241001214789 Basilea Species 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000710185 Mengo virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100264174 Mus musculus Xiap gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010077674 Tetraspanin 25 Proteins 0.000 description 1
- 102000010430 Tetraspanin 25 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 108091011142 collagen binding proteins Proteins 0.000 description 1
- 102000021124 collagen binding proteins Human genes 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000000014 large pre-b cell Anatomy 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000004160 naive b lymphocyte Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000000345 small pre-b cell Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70530505P | 2005-08-03 | 2005-08-03 | |
| US60/705,305 | 2005-08-03 | ||
| PCT/US2006/030250 WO2007019223A1 (en) | 2005-08-03 | 2006-08-02 | Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2616069A1 CA2616069A1 (en) | 2007-02-15 |
| CA2616069C true CA2616069C (en) | 2018-07-31 |
Family
ID=37309396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2616069A Active CA2616069C (en) | 2005-08-03 | 2006-08-02 | Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7919672B2 (enExample) |
| EP (1) | EP1910418B1 (enExample) |
| JP (1) | JP5188969B2 (enExample) |
| CN (3) | CN102443058A (enExample) |
| AT (1) | ATE474853T1 (enExample) |
| CA (1) | CA2616069C (enExample) |
| DE (1) | DE602006015653D1 (enExample) |
| ES (1) | ES2347979T3 (enExample) |
| WO (1) | WO2007019223A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008027986A2 (en) | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
| US20080227688A1 (en) * | 2007-03-13 | 2008-09-18 | Johnston Randal N | Inhibition of viral replication |
| CN112690250B (zh) * | 2008-12-18 | 2024-03-08 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| EP4141108A1 (en) | 2013-12-24 | 2023-03-01 | Kling Biotherapeutics B.V. | Ex vivo antibody production |
| WO2015143284A1 (en) * | 2014-03-21 | 2015-09-24 | The General Hospital Corporation | Essential fatty acid-producing nonhuman transgenic animals and uses thereof |
| IL297997A (en) * | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| CN105274116B (zh) * | 2015-10-21 | 2020-09-29 | 重庆金迈博生物科技有限公司 | 一种制备人源化抗体的核酸分子及其应用 |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| IL263160B2 (en) * | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| CN110373428A (zh) * | 2016-10-08 | 2019-10-25 | 杭州电子科技大学 | 一种促进细胞移植和基因表达的转基因载体系统及其应用 |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| JP2021508471A (ja) | 2017-12-29 | 2021-03-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法 |
| CN111349615B (zh) * | 2018-12-24 | 2024-08-13 | 上海细胞治疗集团股份有限公司 | 制备过表达外源基因的细胞的方法 |
| JP7354306B2 (ja) | 2019-06-27 | 2023-10-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 |
| AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CR20240246A (es) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2509700A (en) * | 1999-01-25 | 2000-08-07 | E.I. Du Pont De Nemours And Company | Polysaccharide fibers |
| CA2634294A1 (en) * | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| WO2004037849A2 (en) * | 2002-10-21 | 2004-05-06 | Regents Of The University Of Minnesota | Transgenic non-human animals with expanded mature b cell and plasma cell populations |
-
2006
- 2006-08-02 CN CN2011103336928A patent/CN102443058A/zh active Pending
- 2006-08-02 ES ES06789294T patent/ES2347979T3/es active Active
- 2006-08-02 WO PCT/US2006/030250 patent/WO2007019223A1/en not_active Ceased
- 2006-08-02 AT AT06789294T patent/ATE474853T1/de not_active IP Right Cessation
- 2006-08-02 US US11/498,571 patent/US7919672B2/en active Active
- 2006-08-02 CN CN2006800333215A patent/CN101263158B/zh active Active
- 2006-08-02 DE DE602006015653T patent/DE602006015653D1/de active Active
- 2006-08-02 CA CA2616069A patent/CA2616069C/en active Active
- 2006-08-02 EP EP06789294A patent/EP1910418B1/en active Active
- 2006-08-02 JP JP2008525183A patent/JP5188969B2/ja active Active
- 2006-08-02 CN CN201310739364.7A patent/CN103710371B/zh active Active
-
2011
- 2011-03-17 US US13/050,792 patent/US8354568B2/en active Active
-
2012
- 2012-12-13 US US13/714,286 patent/US20130102072A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1910418A1 (en) | 2008-04-16 |
| CN102443058A (zh) | 2012-05-09 |
| JP5188969B2 (ja) | 2013-04-24 |
| US20070033661A1 (en) | 2007-02-08 |
| US20110219465A1 (en) | 2011-09-08 |
| CN103710371A (zh) | 2014-04-09 |
| US20130102072A1 (en) | 2013-04-25 |
| CN101263158B (zh) | 2011-12-28 |
| US7919672B2 (en) | 2011-04-05 |
| ATE474853T1 (de) | 2010-08-15 |
| CN103710371B (zh) | 2017-03-01 |
| WO2007019223A1 (en) | 2007-02-15 |
| EP1910418B1 (en) | 2010-07-21 |
| ES2347979T3 (es) | 2010-11-26 |
| CN101263158A (zh) | 2008-09-10 |
| DE602006015653D1 (de) | 2010-09-02 |
| CA2616069A1 (en) | 2007-02-15 |
| US8354568B2 (en) | 2013-01-15 |
| JP2009502203A (ja) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8354568B2 (en) | Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin | |
| US11230697B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
| CA2532117C (en) | Humanized immunoglobulin loci | |
| US20080184380A1 (en) | Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals | |
| US20050153392A1 (en) | Transgenesis with humanized immunoglobulin loci | |
| US10370641B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
| US20040158880A1 (en) | Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |